The American Academy of Audiology, upon detailed appraisal of the recommendations and supporting evidence, has endorsed the American Cochlear Implant Alliance Task Force Guidelines for Clinical Assessment and Management of Adult Cochlear Implantation for Single-Sided Deafness (published in the November/December 2022 issue of Ear and Hearing).
The Academy’s endorsement entails a formal review by the Guidelines and Strategic Documents Committee to determine appropriateness for Academy’s endorsement, review by the expert panel for methodological quality and rigor, and an approval by the Academy Board of Directors. The endorsement process, including information on the procedures related to review for endorsement, types of endorsement, and dissemination, is detailed in the American Academy of Audiology Endorsement of Clinical Practice Documents Developed by External Organizations policy document.
The American Cochlear Implant Alliance guideline reviews the current evidence relevant to the assessment and management of adults with single-sided deafness. A systematic review was conducted on published studies that investigated outcomes of cochlear implant use on measures of speech recognition in quiet and noise, sound source localization, tinnitus perception, and quality of life for this patient population. Findings were combined to provide guidance for the preoperative evaluation and post-activation assessment and management of adults with single-sided deafness.
Acknowledgments
The American Academy of Audiology would like to acknowledge the expert panel convened to review the American Cochlear Implant Alliance Task Force guidelines for endorsement consideration—Jessica Messersmith, PhD, University of South Dakota; Sarah Sydlowski, AuD, PhD, MBA, Cleveland Clinic; and Monika Tiido, AuD, UT Southwestern Medical Center.
Related Academy’s Guidelines
American Academy of Audiology Clinical Practice Guideline: Cochlear Implants
Recent Posts
Academy Advocacy on Capitol Hill for Student Loan Reform and EHDI Support
Last week, Joanne Zurcher, MPP, and Academy member Melissa Heche, AuD, traveled to Capitol Hill to advocate for two important Academy priorities: protecting access to…
A New Era in Hearing Care: FDA Approves OTOF Gene Therapy
In the United States, mutations in the OTOF-gene (otoferlin gene) account for between one percent and eight percent of non-syndromic congenital hearing loss (Ford et…
Academy Board Election Results 2026
We are pleased to announce the newly elected members-at-large and president-elect who will join your Academy Board of Directors. President-Elect The president-elect will serve a…


